NEKTAR THERAPEUTICS

Insider Sales Continue at NEKTAR THERAPEUTICS: CEO and R&D Officer Trim Shares Amid Strong Share Gains and Ongoing Liquidity Playbook

NEKTAR THERAPEUTICS insider Zalevsky sells 5,681 shares at $70, a routine liquidity move that signals confidence in future growth.

NEKTAR THERAPEUTICS
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

03/07/2026, 01:22

3 minutes to read

CEO Robin Howard’s June 10‑K Share Sales Illustrate Planned Insider Liquidity, Not Market Warning

Insider selling stays modest yet strategic: CEO Robin Howard sells 10,000 shares at $60‑$62, reflecting planned liquidity amid a bullish stock and no sign of distress.

NEKTAR THERAPEUTICS
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

19/06/2026, 01:24

3 minutes to read

Nektar R&D Chief Sells Shares on Rule 10b5‑1 Plan, Signals Routine Liquidity Management amid Ongoing Insider Buying Wave

Insightful Nektar insider‑sale analysis: what Jonathan Zalevsky’s Rule 10b5‑1 trade means for shareholders and long‑term confidence in the biotech pipeline.

NEKTAR THERAPEUTICS
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

23/01/2026, 01:47

4 minutes to read